GlassScriptPhysician profile
Mohamed R Och
NPI 1629098496
$44,938.11
in general payments reported to CMS, 2019-2025
31 companies · $675 in 2025
The $675 reported for 2025 was more than what 75% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $6,904 · 2021: $11K · 2022: $7,944 · 2023: $4,568 · 2024: $584 · 2025: $675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,827.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $14,209.93 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $11,575.90 | 2021-2025 | |
| Allergan, INC. | $5,407.45 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $1,901.77 | 2019-2025 | Spravato, Invega Sustenna |
| Alkermes, INC. | $1,745.66 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $1,376.15 | 2019-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $1,257.64 | 2019-2023 | Austedo Xr, Austedo, Uzedy |
| Vanda Pharmaceuticals INC. | $1,149.96 | 2019-2023 | Hetlioz, Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,078.45 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $914.59 | 2019-2023 | Trintellix |
| Lundbeck LLC | $880.17 | 2019-2023 | Rexulti |
| Sunovion Pharmaceuticals INC. | $756.58 | 2019-2022 | |
| Axsome Therapeutics, INC. | $466.39 | 2022-2023 | Auvelity, Sunosi |
| Bausch Health US, LLC | $451.03 | 2021-2023 | Aplenzin, Wellbutrin |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $350.63 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $250.22 | 2022 | |
| Merck Sharp & Dohme LLC | $246.43 | 2020-2023 | Belsomra |
| E.R. Squibb & Sons, L.L.C. | $227.15 | 2024-2025 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $182.33 | 2019-2022 | |
| Corium, LLC | $143.26 | 2022-2023 | Azstarys |
| Eisai INC. | $77.57 | 2020-2021 | |
| Almatica Pharma LLC | $50.54 | 2022 | |
| Arbor Pharmaceuticals, INC. | $47.97 | 2021 | |
| Idorsia Pharmaceuticals US INC | $40.18 | 2022-2023 | Quviviq |
| Jazz Pharmaceuticals INC. | $34.25 | 2019-2021 | |
| Pfizer INC. | $27.02 | 2023 | |
| Braeburn INC. | $19.22 | 2023 | Brixadi |
| Orexo US, INC. | $18.57 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.31 | 2022 | |
| Ironshore Pharmaceuticals INC. | $18.17 | 2019 | |
| Shire North American Group INC | $14.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamed Och listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.